LONDON--(BUSINESS WIRE)--The global gallbladder cancer therapeutics market size is poised to grow by USD 75.79 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of almost 5% during the forecast period.
Read the 133-page research report with TOC on "Gallbladder Cancer Therapeutics Market Analysis Report by type (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW) and Segment Forecasts, 2019 - 2023". Request Free Sample Pages
The market is driven by the rising risk factors for gallbladder cancer. In addition, the advent of targeted therapy is anticipated to further boost the growth of the gallbladder cancer therapeutics market.
Gallbladder cancer is a multifactorial, dependable progression, which makes it difficult to define the risk attributable to one factor. However, obesity is explicitly associated with the development of gallbladder cancer. There are several other risks that increase the chances of developing gallbladder cancer, which includes cholelithiasis, chronic inflammation, and gallbladder polyps. Such rising risk factors for gallbladder cancer are expected to fuel the gallbladder cancer therapeutics market growth during the forecast period.
Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio's SUBSCRIPTION platform
Major Five Gallbladder Cancer Therapeutics Market Companies:
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative medicines. The company’s key offerings include PLATINOL, a cisplatin-based chemotherapy approved for the treatment of gallbladder cancer.
Eli Lilly and Co.
Eli Lilly and Co. is engaged in the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: endocrinology, oncology, cardiovascular, neuroscience, immunology, and others. The company offers GEMZAR, which is an intravenously administered chemotherapy approved for the treatment of various oncology indications, including gallbladder cancer.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. develops and sells various therapeutic drugs and in-vitro diagnostic tools. The company’s key offerings in the market include XELODA, which is a capecitabine-based therapy used for the treatment of various oncology indications, including gallbladder cancer.
Pfizer Inc. develops internal medicine, vaccines, oncology products, inflammation and immunology products, rare disease products, and consumer healthcare products. The company provides ADRUCIL, which is an intravenously administered fluorouracil approved for the treatment of gallbladder cancer.
Sanofi develops, manufactures, and commercializes pharmaceutical products for the treatment of diabetes, cardiovascular diseases, cancers, immunology, inflammation diseases, multiple sclerosis, neurology indications, infectious diseases, and rare diseases. The company’s key offering ELOXATIN is used for the treatment of gallbladder cancer.
Technavio has segmented the gallbladder cancer therapeutics market based on type (and geography.
Gallbladder cancer therapeutics Type Outlook (Revenue, USD Million, 2019 - 2023)
- Combination therapy
Gallbladder cancer therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare are:
Cancer Biologics Market – Global Cancer Biologics Market by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (Asia, Europe, North America, and ROW).
Fallopian Tube Cancer Therapeutics Market – Global Fallopian Tube Cancer Therapeutics Market by product (targeted therapy and chemotherapy) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.